Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New study highlights success of financial toxicity tumor board in reducing cancer treatment costs

2.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

3.

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

4.

Why alarm is easing over a rise in pancreatic cancer among the young

5.

Scholastic performance is a key concern for young cancer patients, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot